Amazon: threat or opportunity for pharmaceuticals?

23 March 2021
amazon_big

Debbie Bowen-Heaton, partner at Oliver Wight, provides an Expert View on how companies can prepare for the disruption Amazon's arrival in Europe's pharmaceutical space will bring.

Following its successful launch in the USA, Amazon applied for ‘Amazon Pharmacy’ trademarks in the UK and European Union (EU) last year.

Together with Amazon’s partnership with the National Health Service (NHS) in the UK, to offer medical advice on its platform Alexa, this is systematic of the way in which Amazon is looking to disrupt and revolutionize the sector.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical